Vijay Kumar
Stock Analyst at Evercore ISI Group
(2.12)
# 2,976
Out of 5,241 analysts
299
Total ratings
38.66%
Success rate
-5.35%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENOV Enovis | Maintains: Outperform | $35 → $36 | $26.12 | +37.83% | 6 | May 8, 2026 | |
| PEN Penumbra | Maintains: Outperform | $345 → $335 | $322.97 | +3.72% | 4 | May 7, 2026 | |
| SYK Stryker | Maintains: Outperform | $365 → $355 | $305.51 | +16.20% | 15 | May 1, 2026 | |
| NVCR NovoCure | Maintains: Outperform | $16 → $20 | $18.05 | +10.80% | 12 | May 1, 2026 | |
| IRTC iRhythm Holdings | Maintains: Outperform | $170 → $160 | $114.16 | +40.15% | 5 | May 1, 2026 | |
| ILMN Illumina | Maintains: Outperform | $150 → $155 | $143.24 | +8.21% | 10 | May 1, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Outperform | $85 → $80 | $62.67 | +27.65% | 8 | Apr 30, 2026 | |
| BLCO Bausch + Lomb | Maintains: In-Line | $17 → $16 | $16.27 | -1.66% | 14 | Apr 30, 2026 | |
| AVTR Avantor | Maintains: In-Line | $8.5 → $8 | $7.94 | +0.76% | 15 | Apr 30, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $58 → $60 | $53.42 | +12.32% | 10 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $93 | $81.34 | +14.33% | 17 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $78 | $53.55 | +45.66% | 10 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $134 → $120 | $84.90 | +41.34% | 20 | Apr 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $108 → $106 | $76.97 | +37.72% | 7 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,515 → $1,425 | $1,041.91 | +36.77% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $52.95 | +5.76% | 8 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $650 → $575 | $448.21 | +28.29% | 14 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $550 → $480 | $428.06 | +12.13% | 16 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $254 → $225 | $164.54 | +36.74% | 5 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $15.25 | +96.72% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $22 | $17.78 | +23.73% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $35 | $16.80 | +108.33% | 11 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $140 | $113.26 | +23.61% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $222 → $232 | $254.66 | -8.90% | 10 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $118 | $96.38 | +22.43% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $82.65 | +45.19% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $2.95 | +1.69% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $333.21 | +6.54% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $100.50 | +59.20% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $144.47 | +100.73% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.60 | +337.50% | 1 | May 31, 2022 |
Enovis
May 8, 2026
Maintains: Outperform
Price Target: $35 → $36
Current: $26.12
Upside: +37.83%
Penumbra
May 7, 2026
Maintains: Outperform
Price Target: $345 → $335
Current: $322.97
Upside: +3.72%
Stryker
May 1, 2026
Maintains: Outperform
Price Target: $365 → $355
Current: $305.51
Upside: +16.20%
NovoCure
May 1, 2026
Maintains: Outperform
Price Target: $16 → $20
Current: $18.05
Upside: +10.80%
iRhythm Holdings
May 1, 2026
Maintains: Outperform
Price Target: $170 → $160
Current: $114.16
Upside: +40.15%
Illumina
May 1, 2026
Maintains: Outperform
Price Target: $150 → $155
Current: $143.24
Upside: +8.21%
GE HealthCare Technologies
Apr 30, 2026
Maintains: Outperform
Price Target: $85 → $80
Current: $62.67
Upside: +27.65%
Bausch + Lomb
Apr 30, 2026
Maintains: In-Line
Price Target: $17 → $16
Current: $16.27
Upside: -1.66%
Avantor
Apr 30, 2026
Maintains: In-Line
Price Target: $8.5 → $8
Current: $7.94
Upside: +0.76%
U.S. Bancorp
Apr 29, 2026
Maintains: In-Line
Price Target: $58 → $60
Current: $53.42
Upside: +12.32%
Apr 24, 2026
Maintains: Outperform
Price Target: $92 → $93
Current: $81.34
Upside: +14.33%
Apr 23, 2026
Maintains: Outperform
Price Target: $80 → $78
Current: $53.55
Upside: +45.66%
Apr 17, 2026
Maintains: Outperform
Price Target: $134 → $120
Current: $84.90
Upside: +41.34%
Apr 9, 2026
Maintains: Outperform
Price Target: $108 → $106
Current: $76.97
Upside: +37.72%
Apr 6, 2026
Maintains: Outperform
Price Target: $1,515 → $1,425
Current: $1,041.91
Upside: +36.77%
Apr 6, 2026
Maintains: Outperform
Price Target: $52 → $56
Current: $52.95
Upside: +5.76%
Apr 6, 2026
Maintains: Outperform
Price Target: $650 → $575
Current: $448.21
Upside: +28.29%
Apr 6, 2026
Maintains: In-Line
Price Target: $550 → $480
Current: $428.06
Upside: +12.13%
Apr 6, 2026
Maintains: Outperform
Price Target: $254 → $225
Current: $164.54
Upside: +36.74%
Apr 6, 2026
Maintains: Outperform
Price Target: $34 → $30
Current: $15.25
Upside: +96.72%
Apr 6, 2026
Maintains: Outperform
Price Target: $23 → $22
Current: $17.78
Upside: +23.73%
Apr 6, 2026
Maintains: Outperform
Price Target: $45 → $35
Current: $16.80
Upside: +108.33%
Apr 6, 2026
Maintains: Outperform
Price Target: $160 → $140
Current: $113.26
Upside: +23.61%
Mar 27, 2026
Maintains: Outperform
Price Target: $222 → $232
Current: $254.66
Upside: -8.90%
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $96.38
Upside: +22.43%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $82.65
Upside: +45.19%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $2.95
Upside: +1.69%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $333.21
Upside: +6.54%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $100.50
Upside: +59.20%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $144.47
Upside: +100.73%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.60
Upside: +337.50%